Trials / Unknown
UnknownNCT04193098
Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC
Phase I Clinical Study of Autologous Cytotoxic T Lymphocyte (CTL) Cell Immunotherapy Combination With PD-1 Inhibitor in the Second-line Treatment of Stage IIIB/IIIC/IV Non-Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, unicentric, open-labe phase I study is to evaluate the safety and effect of autologous cytotoxic T lymphocyte immunotherapy combination with PD-1 inhibitor in the second-line treatment of stage IIIB/IIIC/IV non-small cell lung cancer.
Detailed description
In the stage IIIB/IIIC/IV NSCLC, patients received Toripalimab Injection (PD-1 inhibitor) 240mg, d1; CTL cells venous re-transfusion \>=1x10\^9, d14; Q3W; till disease progresion, or intolerable adverse reactions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CTL | CTL injection |
| BIOLOGICAL | Toripalimab | Toripalimab injection |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2021-06-01
- Completion
- 2021-06-01
- First posted
- 2019-12-10
- Last updated
- 2020-07-07
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04193098. Inclusion in this directory is not an endorsement.